Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors

Moreno N., Holsten T., Mertins J., Zhogbi A., Johann P., Kool M., Meisterernst M., Kerl K.

Research article (journal) | Peer reviewed

Abstract

Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT.

Details about the publication

JournalOncotarget
Volume8
Issue49
Page range84986-84995
StatusPublished
Release year2017
Language in which the publication is writtenEnglish
DOI10.18632/oncotarget.18583
Link to the full texthttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85031493752&origin=inward
KeywordsBRD4; CDK9; Rhabdoid tumors; SMARCB1; Synergistic

Authors from the University of Münster

Meisterernst, Michael
Institute of Molecualr Tumor Biology